India’s Pioneering Advancements in Vaccinology: Challenges and Milestones – Part 2

Year : 2026 | Volume : 16 | Issue : 02 | Page : 1 21
By

Maitry Goel,

Vibha Gupta,

  1. Student, Department of Biotechnology, Jaypee Institute of Information Technology, Sector 62, Noida, Uttar Pradesh, India
  2. Professor, Department of Biotechnology, Jaypee Institute of Information Technology, Sector 62, Noida, Uttar Pradesh, India

Abstract

India has become a global leader in vaccinology, playing a vital role in developing, producing, and distributing vaccines that protect millions of lives. By embracing advances in molecular immunology, recombinant antigen technology, and virus-like particle (VLP) platforms, the country has created affordable vaccines against major diseases, including poliovirus, rotavirus, and SARS-CoV-2. National initiatives, like Mission Indradhanush and Vaccine Maitri, have helped expand immunization coverage, improve public health, and share vaccines with countries in need, reflecting India’s commitment to both national and global health. The development of homegrown vaccines, such as Shanvac-B, showcases how cutting-edge biotechnology can be translated into practical solutions that make a real difference in people’s lives. Strong regulatory frameworks, including the New Drugs and Clinical Trials Rules (2019) and rigorous chemistry, manufacturing, and controls (CMC) standards, ensure that every vaccine is safe, effective, and capable of generating a strong immune response. Innovations in adjuvants, high-yield production methods, and public–private collaborations have further strengthened India’s position in global immunization efforts. With experience in large-scale vaccination drives, research on novel vaccine platforms, and efficient distribution systems, the country is well-prepared to respond swiftly to new health threats. As infectious diseases continue to emerge and public health challenges evolve, India’s dedication to scientific innovation, strategic planning, and international collaboration will remain essential to safeguard communities, enhance long-term resilience, and ensure a healthier future for people both within the country and around the world.

Keywords: Immunogenicity, Mission Indradhanush, SARS-CoV-2, Shanvac-B, Vaccine Maitri

[This article belongs to Research and Reviews: A Journal of Microbiology and Virology ]

How to cite this article: Maitry Goel, Vibha Gupta. India’s Pioneering Advancements in Vaccinology: Challenges and Milestones – Part 2. Research and Reviews: A Journal of Microbiology and Virology. 2026; 16(02):1-21.
How to cite this URL: Maitry Goel, Vibha Gupta. India’s Pioneering Advancements in Vaccinology: Challenges and Milestones – Part 2. Research and Reviews: A Journal of Microbiology and Virology. 2026; 16(02):1-21. Available from: https://journals.stmjournals.com/rrjomv/article=2026/view=238856

Browse Figures

References

  1. Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014 Aug;111(34):12283–12287. doi: 1073/pnas.1400472111. Available from: https://doi.org/10.1073/pnas.1400472111.
  2. Yadav P. Insights From India on Expanding Global Vaccine Production [Internet]. Think Global Health. 2024. Available from: https://www.thinkglobalhealth.org/article/insights-india-expanding-global-vaccine-production.
  3. Vaccines in India – pharmaceuticals industry. Statista. 2025. Available from: https://www.statista.com/outlook/hmo/pharmaceuticals/vaccines/india?currency=USD. Accessed 14 Apr 2025.
  4. Salalli R, Dange JR, Dhiman S, Sharma T. Vaccines development in India: Advances, regulation, and challenges. Clin Exp Vaccine Res. 2023 Jul;12(3):193–208. doi: 7774/cevr.2023.12.3.193.
  5. Tahamtan A, Charostad J, Hoseini Shokouh SJ, Barati M. An overview of history, evolution, and manufacturing of various generations of vaccines. J Arch Mil Med. 2017;5:e12315.
  6. Ministry of Health and Family Welfare. Annual report 2016–17: Organization and infrastructure. New Delhi: Ministry of Health and Family Welfare; 2018. Available from:https://main.mohfw.gov.in/sites/default/files/1201617.pdf.
  7. Howard N, Walls H, Bell S, Mounier-Jack S. The role of National Immunisation Technical Advisory Groups (NITAGs) in strengthening national vaccine decision-making: A comparative case study of Armenia, Ghana, Indonesia, Nigeria, Senegal and Uganda. Vaccine. 2018;36(39):5536–5543. doi: 1016/j.vaccine.2018.07.046.
  8. Sathiaraj E. Better nutrition for a better future. Geneva: James Lind Institute; 2021. Available from: https://www.jli.edu.in/blog/roles-and-responsibilities-ofcdsco.
  9. Indian Council of Medical Research. Announcement: Indian Council of Medical Research reference list. New Delhi: Indian Council of Medical Research; 2017. Available from: http://www.icmr.nic.in/.
  10. Kadam R, Karandikar S. Ethics committees in India: Facing the challenges. Perspect Clin Res. 2012;3(2):50–56. doi: 4103/2229-3485.96446.
  11. World Health Organization (2009). Research ethics committees : basic concepts for capacity-building. World Health Organization. World Health Organization. Available: https://iris.who.int/handle/10665/44108
  12. National Health Mission. Immunization: National Health Mission. Available from: https://nhm.gov.in.
  13. Press Information Bureau. Shri J P Nadda launches pneumococcal conjugate vaccine (PCV) under universal immunization programme (UIP). 2017 May 30. Available from: https://pib.nic.in.
  14. Patra N. Universal immunization programme in India: The determinants of childhood immunization [PDF]. Calcutta: Indian Statistical Institute; 2012.
  15. Chatterjee S, Pant M, Haldar P, Aggarwal MK, Laxminarayan R. Current costs and projected financial needs of India’s universal immunization programme. Indian J Med Res. 2016;143(6):801–808. doi: 4103/0971-5916.192073.
  16. Jafari H, et al. Progress Toward Polio Eradication in India. Journal of Infectious Diseases. 2014;210(Suppl 1):S296–S303.
  17. Social Mobilization Network for Polio Eradication in India: Lessons Learned. New Delhi: UNICEF; 2013
  18. Summan, Amit; Nandi, Arindam; Deo, Sarang; Laxminarayan, Ramanan (2021). “Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush”. Annals of the New York Academy of Sciences. 1502 (1): 110-120
  19. Press Information Bureau. Intensified Mission Indradhanush (IMI) 5.0 campaign concludes all three rounds on 14 Oct 2023. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1966931.
  20. The Hindu Business Line. Vaccine Maitri: A sanjeevini for the world. The Hindu Business Line 2021 Mar 4. Available: https://www.thehindubusinessline.com/news/variety/vaccine-maitri-a-sanjeevini-for-the-world/article62178717.ece
  21. Press Trust of India. 162.9 million Covid vaccine doses supplied to 98 countries: Govt [Internet]. bsindia. Business Standard; 2022. Available from: https://www.business-standard.com/amp/article/current-affairs/162-9-million-covid-vaccine-doses-supplied-to-98-countries-govt-122031501045_1.htm
  22. Coronavirus: India temporarily halts Oxford-AstraZeneca vaccine exports,” BBC News, Mar. 24, 2021. [Online]. Available : https://www.bbc.com/news/world-asia-india-56513371 .
  23. COVID vaccine: India to resume vaccine exports from October,” BBC News, Sep. 21, 2021. [Online]. Available: https://www.bbc.com/news/world-asia-india-58634570
  24. India pledges support to UN to ensure Syria gets COVID vaccines,” NDTV, Mar. 23, 2021. [Online]. Available: https://www.ndtv.com/india-news/india-pledges-support-to-un-to-ensure-syria-gets-covid-vaccines-2382459. .
  25. India’s ‘gift’ to UN peacekeepers: 200,000 COVID vaccine doses. Mint. 2021 Mar 26.
  26. Ravelo JL. The evolution of global health’s ‘best-kept secret’. Devex. 2014 Nov 10.
  27. World Health Organization. GAVI – The global alliance for vaccines and immunizations. WHO. 2022 Apr 5.
  28. Ikilezi G, Augusto OJ, Dieleman JL, Sherr K, Lim SS. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage. Vaccine. 2020;38(3):588–596. doi: 1016/j.vaccine.2019.10.057.
  29. Jaupart P, Dipple L, Dercon S. Has Gavi lived up to its promise? BMJ Glob Health. 2019;4(6):e001789. doi: 1136/bmjgh-2019-001789.
  30. Tsai FJ, Lee H, Fan VY. Perspective and investments in health system strengthening of Gavi, the vaccine alliance. Int Health. 2016;8(4):246–252. doi: 1093/inthealth/ihv063.
  31. Paulson, “Doctors Without Borders criticizes Gates-backed global vaccine strategy,” Humanosphere, May 15, 2012. [Online]. Available: https://web.archive.org/web/20211103200819/https://www.humanosphere.org/global-health/2012/05/doctors-without-borders-criticizes-gates-backed-global-vaccine-strategy/
  32. Doctors Without Borders – USA. Pneumococcal vaccine is launched in Africa, but are donors getting a fair deal from companies? Available from: https://www.doctorswithoutborders.org.
  33. Storeng KT. The GAVI alliance and the ‘Gates approach’ to health system strengthening. Glob Public Health. 2014;9(8):865–879. doi: 1080/17441692.2014.940362.
  34. Directorate General of Health Services. National tuberculosis elimination programme. Ministry of Health and Family Welfare, Government of India. Available from: https://dghs.mohfw.gov.in/national-tuberculosis-elimination-programme.php.
  35. Ministry of Health and Family Welfare, Government of India. India’s immunization drive: A commitment to universal vaccine coverage and health equity. Press release; Apr 2025.
  36. Havisure – India’s first indigenously developed hepatitis A vaccine,” PWOnlyIAS, Jan. 22, 2024. [Online]. Available: https://pwonlyias.com/current-affairs/havisure-vaccine/
  37. Shantha Biotechnics. Shanvac-B. Available from: https://shanthabiotech.com/shanvac_b.asp.
  38. Serum Institute of India Pvt Ltd. Pentavac (PFS/SD) – diphtheria, tetanus, pertussis, hepatitis B and Haemophilus type b conjugate vaccine. Available from: https://www.seruminstitute.com/product_ind_pentavac.php.
  39. Serum Institute of India. CERVAVAC – quadrivalent human papilloma virus vaccine. Available from: https://www.seruminstitute.com/product_ind_cervavac.php.
  40. Bharat Biotech. ROTAVAC – first rota virus vaccine manufacturer. Available from: https://www.bharatbiotech.com/rotavac.html.
  41. Behera P, Singh AK, Subba SH, Mc MA, Sahu DP, Chandanshive PD, et al. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. Hum Vaccin Immunother. 2022;18(1):2034456. doi: 1080/21645515.2022.2034456.
  42. Serum Institute of India Pvt Ltd. COVISHIELD FAQs. 2021 Jul 5. Available from: https://www.seruminstitute.com/health_faq_covishield.php.
  43. Press Information Bureau. Union health minister lists achievements of the union health ministry in the first 100 days of the new government. 2024 Sep 20. Available: https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1732812&reg=48&lang=2.
  44. P. Nair et al., “Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016–2020,” Nature Medicine, 2025. [Online]. Available: https://www.nature.com/articles/s41591-025-03998-9
  45. TypbarTCV|Typhoid Vaccine in India|Vaccine for Typhoid-Bharat Biotech [Internet]. Bharatbiotech.com. 2025. Available from: https://www.bharatbiotech.com/typbartcv.html
  46. COVAXIN – India’s First Indigenous Covid-19 Vaccine | Bharat Biotech [Internet]. Bharatbiotech.com. 2020. Available from: https://www.bharatbiotech.com/covaxin.html
  47. Dey A, Chozhavel Rajanathan TM, Chandra H, Pericherla HP, Kumar S, Choonia HS, et al. (July 2021). “Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models”. Vaccine. 39 (30): 4108–4116. doi:10.1016/j.vaccine.2021.05.098. ISSN 0264-410X. PMC 8166516. PMID 34120764
  48. Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, et al. (August 2022). “Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials”. eBioMedicine. 83 104217. doi:10.1016/j.ebiom.2022.104217. PMC 9372721. PMID 35970020
  49. iNCOVACC – Intranasal Vaccine For Covid-19 | Bharat Biotech [Internet]. Bharatbiotech.com. 2025. Available from: https://www.bharatbiotech.com/intranasal-vaccine.html
  50. Hillchol® | Hillchol Vaccine Manufacturer in India | Bharat Biotech [Internet]. Bharatbiotech.com. 2018. Available from: https://www.bharatbiotech.com/hillchol.html
  51. Ministry of Science and Technology, Government of India. List of licensed human vaccine manufacturing facilities in India. India Science, Technology & Innovation Portal. Available from: https://www.indiascienceandtechnology.gov.in.
  52. Seattle Post-Intelligencer (May 21, 2007). “PATH, influential global health office, marks 30 years”. Archivedfrom the original on June 27, 2021. Retrieved February 13, 2013. Available: PATH, influential global health office, marks 30 years
  53. Indo-Pacific Health Security. Quad vaccine partnership. Department of Foreign Affairs and Trade (DFAT). Available from: https://indopacifichealthsecurity.dfat.gov.au.
  54. Vision IAS. India’s vaccination drives: strategy, obstacles and opportunities. Available from: https://cdn.visionias.in/value_added_material/8d9e6-indias-vaccination-drives_strategy-obstacles-and-opportunities.pdf.
  55. Maitry Goel, Vibha Gupta. Vaccines Through Time: Conventional Foundations and Next-Gen Innovations–Part 1. Research and Reviews: A Journal of Microbiology and Virology. 2026; 16(01):53-70.  Available from: https://journals.stmjournals.com/rrjomv/article=2026/view=238848
Regular Issue Subscription Review Article
Volume 16
Issue 02
Received 09/12/2025
Accepted 04/01/2026
Published 20/01/2026
Publication Time 42 Days

Login

My IP

PlumX Metrics

Support